Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...
Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...
Samsungに所属するAI研究者のAlexia Jolicoeur-Martineau氏が小型かつ高性能なAIモデル「Tiny Recursion Model(TRM)」を開発しました。TRMは再帰的推論と呼ばれる手法を採用しており、わずか700万パラメーターという小型モデルでありながらGemini 2.5 Proを超えるベンチマーク ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する